Navigation Links
MaxCyte Presents a Panel Discussion With Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery - LIVE Q&A to Follow
Date:12/15/2008

GAITHERSBURG, Md., Dec. 15 /PRNewswire/ --MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, announces that, due to popular demand, it will be rebroadcasting its webinar with industry experts on the challenges in developing cell-based screening assays for drug discovery. The broadcast is open to the industry and will be held by webinar on Tuesday December 16th at two convenient times, 9:00 AM and 7:30 PM EST. A live Q&A will follow the broadcast.

One of the respected industry experts who led the discussion was Dr. John Reardon, formerly Senior Vice President of Discovery Research Biology at Glaxo Smith Kline and now Executive Vice President and Chief Scientific Officer at Integrated Oncology Solutions Inc. (IOS) in North Carolina. Dr. Reardon reviewed the complexities of cell transfection technologies and challenged the webinar participants to consider the possibilities of creating more relevant assays if it were possible to transfect any molecule into any cell at any scale, while maintaining biological integrity and high quality standards. His discussion offered compelling arguments as to how the MaxCyte(R) STX System can reduce bottlenecks and improve the productivity of drug discovery groups.

Dr. James Brady, Director of Technical Applications at MaxCyte, led the webinar participants through a technical presentation of the MaxCyte(R) STX(TM) Scalable Transfection System. Dr. Brady demonstrated how the MaxCyte STX technology enables the large scale transfection of primary cells, cell lines, and stem cells with single and multiple loading agents at the same time, resulting in more relevant screening systems.

According to MaxCyte CEO Doug Doerfler, "We were delighted with the response to our previous webinar on the MaxCyte STX technology and the interest in continuing with the live panel discussion. The MaxCyte STX is being viewed by the pharmaceutical industry as an enabling technology for cell modification for both research and larger scale cell-based applications in drug discovery. The MaxCyte STX can produce billions of transfected cells in minutes compared to current time-consuming and inconsistent methods. This is possible even for large scale transfection of primary cell lines. More assays can be developed and performed in a shorter period of time, increasing the likelihood of finding a successful drug candidate."

To register for the free webinar, visit www.maxcyte.com and click on the registration link. MaxCyte scientists will be available after the webinar to answer any technical questions relative to the performance and operation of the MaxCyte STX Scalable Transfection System. A recording of the webinar will be available on the MaxCyte website after the event.

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. The MaxCyte transfection technology was originally developed as an enabling technology for cell therapy and is currently being used in a number of clinical trials around the world. Drawing upon this expertise in cell loading for cell therapy, MaxCyte introduced this transfection technology into drug discovery applications as the MaxCyte(R) STX(TM) Scalable Transfection System. The MaxCyte STX allows for the rapid, scalable, and reagent-free cell transfection for cell based assays, preclinical protein production, and other cell-based applications.

For more information, www.maxcyte.com


'/>"/>
SOURCE MaxCyte, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology
2. MaxCyte to Present at the BIO CEO & Investor Conference
3. MaxCyte to Present at the Phacilitate Cell and Gene Therapy Forum 2008
4. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
5. Medicsight PLC Presents New Data at RSNA 2008 Further Supporting Relevance of Computer-Aided Detection (CAD) and Image Analysis Software in Early Colon Cancer Screening and Diagnosis
6. CVS Caremark Presents Influenza Vaccine Data at Rescheduled 2008 DMAA Annual Meeting
7. Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile
8. Sonic Innovations Presents Donation to the Armed Forces Foundation
9. HMS Presents 4th Annual Heroes of Healthcare Awards
10. HealthEdge(R) Presents Award-Winning HealthRules(R) Technology Platform at the 2008 Gartner Healthcare Summit
11. Hearing Loss Presents a Significant Challenge for Rising Number of Caregivers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... , ... August 23, 2017 , ... Drs. Steven White ... in Cornelius, NC. By taking advantage of this offer, valued at more than ... regular six-month hygiene cleaning from the dentist, patients receive a complimentary professional whitening procedure. ...
(Date:8/23/2017)... ... August 23, 2017 , ... ... to prove the safety and efficacy of HBOT in treating and helping to ... US, points to research showing the similarities of the wounds to the brain ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... The Stevie® Awards have announced the winners ... Awards , the world’s premier business awards competition. , Nominees in the 2017 IBAs were ... by a points system based on the total number of awards won in the IBAs ...
(Date:8/23/2017)... ... August 23, 2017 , ... PreCheck, Inc., a ... 2017 Inc. 5000 with a three-year sales growth of 49 percent . The ... comprises the most comprehensive look at America’s independent entrepreneurs. This represents PreCheck’s fifth ...
(Date:8/23/2017)... ... August 23, 2017 , ... Arizona Spine ... nationally that earned the designation of High Performing Hospitals by U.S. News & World ... indicates a hospital was significantly better than the national average in a given ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... that its Board of Directors has approved the payment of ... of 2017. The cash ... about October 27, 2017 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
(Date:8/7/2017)... Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced ... comparisons, unless otherwise noted, are to the quarter ended June ... Quarter 2017 Highlights include: Revenue of ... Total prescriptions dispensed of 220,000, compared to ... Gross profit per prescription dispensed of ...
(Date:8/4/2017)... -- The search for test results that can be ... long been the goal of healthcare providers and the ... largest meeting of lab professionals and IVD firms this ... Kalorama Information.  The firm said scores of companies with ... and software were at the American Association for Clinical ...
Breaking Medicine Technology: